SIM
MRKR icon

Spark Investment Management’s Marker Therapeutics MRKR Stock Holding History

Spark Investment Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,940
Closed -$36K – 197
2020
Q1 		$36K Buy
+1,940
New +$49.4K 0.02% 327

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Spark Investment Management's MRKR Position: Q2 2020 in Review

Spark Investment Management sold out of Marker Therapeutics (MRKR) in Q2 2020, closing a stake of 1,940 shares — an estimated $36K sold.

Spark Investment Management first reported a position in MRKR in Q1 2020 and held it in 1 quarter. The position peaked at $36K in Q1 2020. 63 funds tracked by Wall St. Rank hold MRKR as of Q2 2020.

  • Spark Investment Management reported no remaining Marker Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Spark Investment Management sold 1,940 Marker Therapeutics shares in Q2 2020, an estimated $36K.
  • Spark Investment Management first reported a position in Marker Therapeutics in Q1 2020 and held it in 1 quarter.
  • Spark Investment Management's Marker Therapeutics position peaked at $36K in Q1 2020.
  • 63 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.